


GRL0617

## Chemical Properties

CAS No. : 1093070-16-6  
 Formula: C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O  
 Molecular Weight: 304.39  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

|                            |   |
|----------------------------|---|
| Description                | GRL0617 is a selective and competitive noncovalent inhibitor of SARS-CoVPLpro and deubiquitinase (IC <sub>50</sub> : 0.6 μM, K <sub>i</sub> : 0.49 μM). |
| Targets(IC <sub>50</sub> ) | DUB,SARS-CoV  |

## Solubility Information

|                     |   |
|---------------------|---|
| Solubility          | DMSO: 166.7 mg/mL (547.65 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)   |
| In vivo Formulation | 10% DMSO+90% Saline: < 10 mg/mL (32.85 mM),Lower concentrations may be soluble, but exact solubility limit is unknown.<br>10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (32.85 mM),Solution.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

## Preparing Stock Solutions

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 3.2853 mL | 16.4263 mL | 32.8526 mL |
| 5 mM  | 0.6571 mL | 3.2853 mL  | 6.5705 mL  |
| 10 mM | 0.3285 mL | 1.6426 mL  | 3.2853 mL  |
| 50 mM | 0.0657 mL | 0.3285 mL  | 0.6571 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24.

Yan H, Liu Z, Yan G, et al. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors. Virology. 2022

Li M, Bei Z C, Yuan Y, et al. In-cell bioluminescence resonance energy transfer (BRET)-based assay uncovers ceritinib and CA-074 as SARS-CoV-2 papain-like protease inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2024, 39(1): 2387417.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481